- Home
- FCBC vs STOK Comparison
FCBC vs STOK Comparison
Compare FCBC & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FCBC
- STOK
- Stock Information
- Founded
- FCBC 1874
- STOK 2014
- Country
- FCBC United States
- STOK United States
- Employees
- FCBC N/A
- STOK N/A
- Industry
- FCBC Major Banks
- STOK Biotechnology: Pharmaceutical Preparations
- Sector
- FCBC Finance
- STOK Health Care
- Exchange
- FCBC Nasdaq
- STOK Nasdaq
- Market Cap
- FCBC 778.6M
- STOK 721.4M
- IPO Year
- FCBC 1992
- STOK 2019
- Fundamental
- Price
- FCBC $41.85
- STOK $9.80
- Analyst Decision
- FCBC Hold
- STOK Strong Buy
- Analyst Count
- FCBC 1
- STOK 8
- Target Price
- FCBC $38.00
- STOK $21.83
- AVG Volume (30 Days)
- FCBC 34.6K
- STOK 896.3K
- Earning Date
- FCBC 01-28-2025
- STOK 11-05-2024
- Dividend Yield
- FCBC 2.96%
- STOK N/A
- EPS Growth
- FCBC N/A
- STOK N/A
- EPS
- FCBC 2.74
- STOK N/A
- Revenue
- FCBC $163,169,000.00
- STOK $16,742,999.00
- Revenue This Year
- FCBC N/A
- STOK $105.42
- Revenue Next Year
- FCBC N/A
- STOK N/A
- P/E Ratio
- FCBC $15.06
- STOK N/A
- Revenue Growth
- FCBC 7.32
- STOK 81.08
- 52 Week Low
- FCBC $31.00
- STOK $4.09
- 52 Week High
- FCBC $49.02
- STOK $17.58
- Technical
- Relative Strength Index (RSI)
- FCBC 50.16
- STOK 41.94
- Support Level
- FCBC $39.97
- STOK $8.42
- Resistance Level
- FCBC $41.40
- STOK $9.77
- Average True Range (ATR)
- FCBC 1.04
- STOK 0.65
- MACD
- FCBC 0.22
- STOK -0.02
- Stochastic Oscillator
- FCBC 82.16
- STOK 41.69
About FCBC First Community Bankshares Inc. (VA)
First Community Bankshares Inc is a financial holding company that provides commercial banking products and services. The company is engaged in providing demand deposit accounts, savings, and money market accounts, certificates of deposits; commercial, consumer, and real estate mortgage loans, and lines of credit; various credit card, debit card, and automated teller machine card services; corporate and personal trust services; investment management services and life, health, and property and casualty insurance products. The company's revenue is mainly derived from interest, fees, and commissions.
About STOK Stoke Therapeutics Inc.
Stoke Therapeutics Inc is engaged in addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, it is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. The company primarily operates in the U.S.